Association Between Trimethylamine N-oxide and Adverse Kidney Outcomes and Overall Mortality in Type 2 Diabetes Mellitus
Main finding · Doubling of serum creatinine or progression to ESKDResult — go to the resultFold increase in risk 6.45Authors' conclusion
Patients with T2D with elevated circulating TMAO levels are at higher risk of doubling serum creatinine, progressing to ESKD, and mortality. TMAO is a potential biomarker for kidney function progression and mortality in patients with T2D.
Study context
- Population
- Patients with T2D recruited October 2016–June 2020, monitored every 3 months until December 2021
- Participants
- 440 patients
- Exposure
- Highest vs lowest serum TMAO tertile
- Outcome
- Doubling of serum creatinine or progression to ESKD necessitating dialysis
- Follow-up
- Median 4 years
Methodological detailspropensity score weighting
- Propensity score weighting
Main finding
As reported in the abstract
Doubling of serum creatinine or progression to ESKD
Fold increase in risk
6.45
- Patients with doubling of serum creatinine or end-stage kidney disease (ESKD) (whole cohort)
- 26 (5.9%)
Observational data: associations, not effects.
Further findings
| Outcome | Fold elevated risk |
|---|---|
| Rapid 30% decline in eGFR within 2 yearsAfter propensity score weighting | 5.86 |
All-cause mortality
- Stepwise increase in serum TMAO associated with all-cause mortality
Original publication
Association Between Trimethylamine N-oxide and Adverse Kidney Outcomes and Overall Mortality in Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. Published 24 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →